Home / Meet the Oncolines Team at the AACR Annual Meeting 2026
Meet the Oncolines Team at the AACR Annual Meeting 2026
Oncolines, a Symeres company, will be attending the AACR Annual Meeting 2026 in San Diego from April 17–22, where researchers, biotech, and pharmaceutical leaders come together to share the latest advances in cancer science and new therapeutic approaches.
At this year’s meeting, our team will also present three scientific posters, highlighting new insights into drug response biomarkers, targeted therapies, and resistance mechanisms across diverse cancer models.
During AACR, we look forward to discussing how we can support your programs, from early oncology discovery through to translational research challenges.
If you’re attending AACR, we would welcome the opportunity to connect and explore how Oncolines’ oncology-focused capabilities, supported by Symeres’ broader expertise, can help move your programs forward.
Who may benefit from meeting with Oncolines
• Biotech companies advancing oncology programs
• Teams using in vitro models to support discovery decisions
• Organizations seeking to accelerate early-stage research through outsourcing
• Researchers working on novel targets or mechanisms in cancer biology
What we can discuss
• Oncology models for target validation and compound profiling
• Drug response data and biomarker identification
• Translational insights to guide early development decisions
• Resistance mechanisms and candidate selection
Attending From Oncolines
Members of the Oncolines team attending AACR bring a strong combination of scientific expertise and industry experience across oncology research, translational science, and business development.
Dimitri Pappaioannou, Li-Ming Liang, Jorg Benningshof, Jeffrey Kooijman, and Kirsten Kevenaar will be on-site throughout the event, available to discuss how Oncolines supports oncology drug discovery through high-quality data, biomarker insights, and translational research strategies.
Together, the team works closely with biotech and pharmaceutical partners to generate robust, decision-ready data that helps guide early discovery and accelerate progress toward the clinic.
AACR 2026 Poster
Presentations
Oncolines will present three scientific posters at the AACR Annual Meeting 2026, highlighting research on drug response biomarkers, targeted therapies, and resistance mechanisms across diverse cancer models.
Cellular comparison of a covalent and non-covalent WRN inhibitor reveals shared and unique response biomarkers
Authors:
Gerarda van de Kamp, Daphne J.F. Kluitmans, Tsang W. Lam, Jeroen A.D.M. de Roos, J.T.M. Melis, Jeffrey J. Kooijman, Jorg C.J. Benningshof
Poster details:
Poster #: 235
Date: April 19, 2026
Time: 2:00 PM – 5:00 PM
Location: Poster Section 11
Board number: 6
Distinct response profiles of TROP2-targeting ADCs Dato-DXd and sac-TMT across a large panel of cancer cell lines
Authors:
Janneke J.T.M. Melis, Eef F.P. Smits, Karsten P.F. van Doorn, Tsang W. Lam, Jeroen A.D.M. de Roos, Daphne J.F. Kluitmans, Jeffrey J. Kooijman, Guido J.R. Zaman, Jorg C.J. Benningshof
Poster details:
Poster #: 354
Date: April 19, 2026
Time: 2:00 PM – 5:00 PM
Location: Poster Section 15
Board number: 13
Characterization of intrinsic and acquired resistance to KRASG12C inhibitors across a broad collection of cancer cell line models
Authors:
Jeffrey J. Kooijman, Kirsten J.W. Kevenaar, Daphne J.F. Kluitmans, Laura D.R. van Zelst, Bente Timmers, Tsang W. Lam, Jeroen A.D.M. de Roos, Yvonne Grobben, Janneke J.T.M. Melis, Guido J.R. Zaman, Jorg C.J. Benningshof
Poster details:
Poster #: 1879
Date: April 20, 2026
Time: 9:00 AM – 12:00 PM
Location: Poster Section 19
Board number: 12